"Podophyllotoxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
| Descriptor ID |
D011034
|
| MeSH Number(s) |
D02.455.426.559.389.140.450.777 D02.455.426.559.847.638.960.675 D04.615.638.960.675
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Podophyllotoxin".
Below are MeSH descriptors whose meaning is more specific than "Podophyllotoxin".
This graph shows the total number of publications written about "Podophyllotoxin" by people in this website by year, and whether "Podophyllotoxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Podophyllotoxin" by people in Profiles.
-
Ozuah NW, Dahmoush HM, Grant FD, Lehmann LE, LaCasce AS, Billett AL, Margossian SP. Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation. Pediatr Blood Cancer. 2018 Jan; 65(1).
-
Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008 Jan 01; 26(1):90-5.
-
Jain N, Lam YM, Pym J, Campling BG. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer. 1996 May 01; 77(9):1797-808.
-
Nissen NI, Pajak TF, Leone LA, Bloomfield CD, Kennedy BJ, Ellison RR, Silver RT, Weiss RB, Cuttner J, Falkson G, Kung F, Bergevin PR, Holland JF. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. Cancer. 1980 Jan 15; 45(2):232-5.
-
Bellet RE, Catalno RB, Mastrangelo MJ, Berd D, Koons LS. Phase II trial of VM-26 in patients with metastatic malignant melanoma. Cancer Treat Rep. 1978 Mar; 62(3):445-7.